Article Details
Retrieved on: 2024-05-23 20:07:13
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article details AbbVie's acquisition of Landos Biopharma, enhancing its biopharma portfolio with NX-13, an investigational treatment for ulcerative colitis and Crohn's disease. This acquisition underscores AbbVie's focus on autoimmune diseases and innovative therapies.
Article found on: www.prnewswire.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here